Santhera Pharmaceuticals Holding Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Orlando Oliveira
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | no data |
| CEO ownership | n/a |
| Management average tenure | 1.9yrs |
| Board average tenure | 3.1yrs |
Recent management updates
Recent updates
CEO
Orlando Oliveira (50 yo)
Mr. Orlando Oliveira was Chief Commercial Officer of Zenas BioPharma Limited since 2024 until 2026. He is Senior Vice President, Head of International at Mirati Therapeutics (acquired by BMS). He was Chief...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Chairman | 9.3yrs | CHF 200.00k | 0.42% $ 1.1m | |
| Chief Medical Officer | no data | no data | 0.47% $ 1.3m | |
| Chief Executive Officer | no data | no data | no data | |
| Chief Financial Officer | 1.4yrs | no data | no data | |
| Chief Technology Officer | 2.5yrs | no data | 0.030% $ 81.6k | |
| Head of Compliance | 11.4yrs | no data | no data | |
| Chief Legal Officer & Corporate Secretary | 1.9yrs | no data | 0.043% $ 116.2k | |
| Head of Global Marketing & Partner Management | no data | no data | no data | |
| Global Head of People & Culture | 4.3yrs | no data | no data | |
| Executive Vice President of Corporate Planning & Business Development | no data | no data | no data | |
| Chief Commercial Officer | less than a year | no data | no data |
Experienced Management: SPHD.F's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Chairman | 9.3yrs | CHF 200.00k | 0.42% $ 1.1m | |
| Independent Non Executive Director | 3.1yrs | CHF 135.00k | 0.23% $ 620.2k | |
| Non Executive Independent Director | 9.3yrs | CHF 145.00k | 0.22% $ 597.3k | |
| Director | 1.2yrs | CHF 92.74k | no data | |
| Director | less than a year | no data | no data |
Experienced Board: SPHD.F's board of directors are considered experienced (3.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/26 21:47 |
| End of Day Share Price | 2026/04/28 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Santhera Pharmaceuticals Holding AG is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Richard Parkes | Piper Sandler Companies |
| null null | RBC Capital Markets |
| Christian Glennie | Stifel, Equities Research |